NVTA | Invitae Corporation Stock Overview

(Stock Exchange: NYSE)

Day's Range	0.0160 - 0.0240
52 Week Range	0.0150 - 2.3400
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	22,459,258
Average Volume	12,701,614
Shares Outstanding	286,492,992
Market Cap	5,443,367
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2015-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	0.00
Forward P/E Ratio	N/A
EPS	-5.36
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1,700
Country	USA
Website	NVTA

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

NVTA's peers: A, CDNA, CRL, DHR, EXAS, FLGT, GH, ME, MYGN, NEO, OPK, PACB, PSNL, TMO, TWST

*Chart delayed

Analyzing fundamentals for NVTA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see NVTA Fundamentals page.

Watching at NVTA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NVTA Technicals page.